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S U M M A R Y
The diagnosis of dog-mediated rabies in humans and animals has greatly beneﬁted from technical
advances in the laboratory setting. Approaches to diagnosis now include the detection of rabies virus
(RABV), RABV RNA, or RABV antigens. These assays are important tools in the current efforts aimed at the
global elimination of dog-mediated rabies. The assays available for use in laboratories are reviewed
herein, as well as their strengths and weaknesses, which vary with the types of sample analyzed.
Depending on the setting, however, the public health objectives and use of RABV diagnosis in the ﬁeld
will also vary. In non-endemic settings, the detection of all introduced or emergent animal or human
cases justiﬁes exhaustive testing. In dog RABV-endemic settings, such as rural areas of developing
countries where most cases occur, the availability of or access to testing may be severely constrained.
Thus, these issues are also discussed along with a proposed strategy to prioritize testing while access to
rabies testing in the resource-poor, highly endemic setting is improved. As the epidemiological situation
of rabies in a country evolves, the strategy should shift from that of an endemic setting to one more
suitable for a decreased rabies incidence following the implementation of efﬁcient control measures and
when nearing the target of dog-mediated rabies elimination.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
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The development of rabies diagnostic tests began after the
routine inoculation of rabbits with rabies virus (RABV)-infected
brain and saliva samples in 1880,1 and the identiﬁcation of Negri
bodies after 1903.2,3 Several different assays and diagnostic
approaches are now available, and these represent important
assets in the renewed global efforts to eliminate dog-mediated
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).operational setting, especially in countries with a high caseload of
dog-mediated rabies? In what sequence? For which expected level
of performance?5 This review comprises an overview of currently
available assays and their strengths and weaknesses. Furthermore,
a rabies testing strategy based on the authors’ ﬁeld experience is
proposed. The assays are examined by type and in terms of the type
of sample used and their usefulness in the endemic and non-
endemic settings. The aim of this review is to guide virologists on
the constraints and priorities of surveillance and detection, as well
as animal and human rabies programme managers on the
diagnostic methods and their performance.
2. Principles of RABV diagnostic tests
The various available reference diagnostic approaches resulting
from international and academic initiatives have been describedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
V. Duong et al. / International Journal of Infectious Diseases 46 (2016) 107–114108extensively in previous publications.2,6–8 Their principles, as well
as those of non-reference techniques – some recently developed9–
11 – are summarized in Table 1.
2.1. Detecting virus: inoculation tests
Historically and in the research setting, RABV infection is
identiﬁed by infecting cells and detecting virus. This can be done
either through the mouse inoculation test (MIT) or by inoculationTable 1
Summary of RABV laboratory techniques and their advantages and limitations
Test Principle Advant
Detecting viral replication
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young mice for virus
ampliﬁcation
Sensitiv
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Reverse-transcriptase PCR (RT-
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further
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transcriptase PCR (RT-qPCR)
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and ampliﬁes it using speciﬁc
primers and probes with
detection of PCR products in
real time
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Direct ﬂuorescent antibody
test (DFAT)
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rabies virus antigens by means
of ﬂuorescence microscopy
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brain s
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RABV, rabies virus; WHO, World Health Organization; BSL, biosafety level; FITC, ﬂuoreof samples onto cultures of murine neuroblastoma or other cells
(rapid tissue culture infection test, RTCT).8,12 Following intracere-
bral inoculation of mice aged 3–4 weeks, MIT test results are
available after an incubation period of up to 28 days. Some strains
are associated with a longer incubation period. In laboratories with
cell culture facilities and an appropriate level of bio-containment,
the RTCT provides results within 24–48 h, which is far quicker than
intracerebral inoculation.13,14 Although it is more sensitive to toxic
or bacterial contaminants, its sensitivity is comparable to that ofages Limitations Ref.
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laboratory)
12,15
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 nucleotide sequencing
Time- and resource-intensive;
cross-contamination and false-
positives are a risk; no
commercial diagnostic kits
currently available
2,12,29
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ble to any sample;
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tional RT-PCR;
speciﬁc probes
Single sequence mismatch
between the primer or probe
sequence and the target viral
sequence may alter the
sensitivity of the test and even
cause false-negative results;
PCR products are too short and
unsuitable for nucleotide
sequencing; no commercial
diagnostic kits currently
available
12,29,30
andard for fresh or ﬁxed
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en; results obtained
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 available
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and a costly ﬂuorescence
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12,29,35–41
sensitive and speciﬁc
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d rapidly
Dedicated for research
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12,29,45
scein isothiocyanate; OIE, World Organization for Animal Health.
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detection of the virus must therefore be evidenced by direct
ﬂuorescent antibody testing (DFAT, see below). In addition, MIT
requires animal facilities to produce mice (or a supplier that can
quickly provide animals of a suitable age in sufﬁcient numbers), as
well as animal facilities with a high level of bio-containment
(ASL3) to maintain the inoculated animals. Animal ethics regula-
tions also recommend avoiding the use of animals when an
efﬁcient cell culture system exists.
As results are usually required urgently and due to animal
protection issues, the World Health Organization (WHO),8,16 as
well as the World Organization for Animal Health (OIE),17 now
recommend replacing the MIT with the isolation of RABV in cell
culture whenever possible.
2.2. Detecting viral RNA in samples
The international health organizations do not currently
consider molecular assays to be reference techniques for the
post-mortem diagnosis of RABV in humans and animals. However,
they are recommended for intra vitam diagnosis in humans.
Although they require laboratory technicians to be trained and
validated in molecular techniques, a PCR assay has been shown to
be more sensitive than DFAT for the detection of lyssaviruses.18
2.2.1. Reverse-transcriptase PCR (RT-PCR)
RT-PCR is the method most often used to detect RABV RNA for
intra vitam diagnosis of rabies in humans. Saliva samples or skin
biopsies taken at the nape of the neck (being careful to include hair
follicles)19 can be tested using this technique. The test reaches
100% sensitivity when at least three successive saliva samples are
collected at 3- to 6-h intervals (due to irregular viral shedding) and
tested.19 Positive results can be obtained as soon as the patient is
admitted. Human and animal brain samples collected by various
methods can also be tested with this technique, even when they
have been kept at relatively high ambient temperatures or when
they have become degraded.20–24 Several sets of more or less
consensual primers for RABV have been developed. In some cases,
primers speciﬁc for variant types of RABV have been developed for
precise and geographically limited purposes, especially research.
Although time- and resource-intensive, the sequencing of PCR
amplicons can improve the speciﬁcity of the technique. Speciﬁcity
is very high when the technique is implemented rigorously, but
false-negatives and false-positives may occur. RT-PCR is highly
susceptible to cross-contamination in the operational setting,
unless standardization and procedures are stringent for the PCR
itself and for the sample extraction2 and reverse transcription of
the RNA.
Other promising virus detection techniques have been devel-
oped, such as loop-mediated isothermal ampliﬁcation (LAMP)25,26
and nucleic acid sequence-based ampliﬁcation (NASBA).27,28 These
are suited to developing settings as they require less sophisticated
equipment and are less costly.
2.2.2. Real-time reverse transcriptase PCR (RT-qPCR)
These assays are based on the transcription of viral RNA to cDNA
before ampliﬁcation (RT). This phase is followed by PCR, which
uses speciﬁc primers and probes or a dye to provide real-time
quantiﬁcation of DNA. These assays reduce the risk of cross-
contamination thanks to closed tubes and show an improved
sensitivity compared to conventional RT-PCR protocols.2,12,29,30
However, as the probes used are highly speciﬁc for known
sequences, sequence mismatch between the primer/probe
sequences and the target viral sequence may adversely affect
the sensitivity of the test, leading to false-negative results. Because
the PCR fragments generated are usually very short, thesequencing of the amplicons may provide diagnostic conﬁrmation
but cannot be used for in-depth molecular phylogenetic analy-
ses.31
2.3. Detecting viral antigens
2.3.1. Direct ﬂuorescent antibody testing (DFAT)
DFAT is the main assay used worldwide; it is the WHO and OIE
recommended gold standard for the diagnosis of rabies in fresh or
frozen brain samples. The latter are important in tropical countries,
as preserving fresh samples at 4 8C is often a challenge.2,8,32,33 This
assay is based on attaching ﬂuorescein isothiocyanate (FITC) to
polyclonal antibodies targeting the RABV ribonucleocapsid, or
monoclonal antibodies targeting the RABV nucleoprotein (N). If the
targeted RABV antigen is present in the sample ﬁxed on a slide,
antibodies attach to it, remain attached despite washing, and can
be observed using a ﬂuorescence microscope.12,33 Results are
available within 1–2 h and are expressed as positive or negative.
The sensitivity and speciﬁcity of DFAT nears 99% in an experienced
laboratory, but is extremely observer-dependent.14,34 At least two
observers must spend enough time on each slide once the quality
of the sample has been ensured. This test is best performed on fresh
brain samples; the reliability of this assay to diagnose rabies in
degraded animal brain samples or corneal smears is low.12
2.3.2. Rapid rabies enzyme immunodiagnosis (RREID)
ELISA techniques have been adapted to detect RABV antigens in
samples using monoclonal or polyclonal antibodies. These use
microplates coated with puriﬁed polyclonal or monoclonal anti-
RABV IgG targeting the nucleocapsid. Several versions of these
assays have been developed (RREID, WELYSSA, etc.) and some have
been commercially available for some time.35–42 They have been
shown to be sensitive and speciﬁc and can be applied even to
partially degraded brain samples.12 Test results can be evaluated
qualitatively with the naked eye. However, these techniques are
less sensitive than DFAT (96% agreement between DFAT and RREID
test results).8,12 For this reason, they should not replace DFAT in
laboratories where DFAT is already performed. These are now
implemented in a very limited number of countries, using home-
made reagents.
2.3.3. Rapid immunodiagnostic test (RIDT)
The Antigen Rapid Rabies Ag Test Kit (BioNote, Inc., Gyeongi-do,
Republic of Korea) is a lateral ﬂow device based on a qualitative
chromatographic immunoassay developed for the detection of
RABV antigen in fresh animal brain tissue (e.g., canine, bovine,
raccoon dog). This type of new RIDT appears suited to the ﬁeld and
frontline laboratories. It is performant (speciﬁcity and sensitivity)
for brain samples from any animal and is highly dependent on the
antibodies (polyclonal or monoclonal) used. This test has a
sensitivity ranging from 91.7% to 96.9% and a speciﬁcity ranging
from 98.9% to 100% when compared to a ﬂuorescent antibody
test.11,43,44 Furthermore, a result can be obtained within 15–
20 min, including the preparation time. This test appears to be very
accurate in detecting RABV antigen, but other tests are required if
questionable results are obtained. However, the RIDT kit requires
further validation before it can be recommended for use by either
the OIE or WHO. At this stage, the RIDT should be implemented (1)
for research purposes only, or (2) in frontline laboratories to
improve the surveillance and control of rabies in remote places
from which the shipment of samples to a central laboratory would
be difﬁcult or even impossible (or where classical rabies laboratory
diagnosis using recommended techniques cannot be established
for ﬁnancial or logistical reasons). Many different products using
the same methodology are commercially available and these
exhibit highly variable intrinsic properties. Laboratories aiming to
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the speciﬁcity and sensitivity – or should rely on available
evaluations performed by international reference laboratories –
before routine use.
2.3.4. Direct rapid immunohistochemical test (dRIT)
This promising method was developed recently by the US
Centers for Disease Control and Prevention (CDC). It is based on the
detection of rabies N protein in brain smears ﬁxed in formalin,
using highly concentrated monoclonal antibodies in the presence
of streptavidin peroxidase and a substrate colouring agent. Test
results are available within 1 h. This test can be implemented in
the ﬁeld and no ﬂuorescence microscope is required.9,12,29,45 The
estimated sensitivity and speciﬁcity approach 100% when com-
pared to a ﬂuorescent antibody test.9,10 This method can also be
used for samples that have been frozen or preserved in glycerol.
Cost-effective indirect immunochemistry assays have been devel-
oped that can also provide indications on the RABV variant.46 A
major concern, however, is access to uninterrupted supplies of
controlled batches of monoclonal antibodies, which are only
available through a few laboratories specialized in rabies diagno-
sis.12
2.4. Detecting antibodies
The detection of antibody in serum in the absence of a history of
rabies vaccination, or in cerebrospinal ﬂuid (CSF), provides indirect
evidence of rabies infection. However, the interpretation of test
results may be difﬁcult, since the host immune response may vary
among individuals: the sensitivity and negative predictive value of
antibody detection methods in rabies patients is very poor,12,47 as
patients with suspected rabies overwhelmingly die before they can
mount an antibody response. The antibody response is only
detectable in the blood (or CSF) after 8–10 days,48 while the
majority of human rabies deaths occur around 6 days after the
onset of clinical signs.49 The poor yield of this technique has been
shown in a series of human rabies cases.50,51 These tests are thus
better suited to assess the protection of laboratory or veterinary
workers or of pets before transboundary travel, or to check for the
appropriate immune response in patients receiving post exposure
prophylaxis (PEP) as part of research (vaccine evaluation,
seroprevalence studies). Considering these constraints and the
low sensitivity in the context of rabies diagnosis in humans and
animals, the techniques used for serology will not be described
here.
3. Why and when should we diagnose rabies?
In non-endemic settings, it is imperative that all suspected
human and animal cases be documented. Rabies laboratory
diagnosis is essential to detect the importation or emergence of
rabies and to guide the public health response or individual case
management.
In endemic settings, the early diagnosis of rabies in the head of a
suspect animal after euthanasia or natural death (the biting
animal) is essential, as it can help inform PEP and the consequent
need for rabies immunoglobulin. Assays such as RIDT and dRIT (or
ELISA assays, such as RREID, if available) offer the possibility of
testing the biting animal’s head at frontline bite centres to guide
timely and adequate PEP for bite victims in rural settings of
endemic countries, where most human rabies deaths occur.
However, a diagnosis of ‘probable rabies’ in humans can routinely
rely simply on the presence of a bite from a potentially rabid dog or
other mammal and clinical signs in the patient, especially those
compatible with furious rabies.49 Laboratory diagnosis remains
essential in the endemic setting to guide public health surveillancerather than individual patient management for an incurable
disease. Testing is also helpful in human cases of ‘paralytic’ rabies,
as encephalitis may be caused by RABV or several other pathogens
co-circulating in many rabies-endemic settings.52,53 Finally, when
the biting dog’s head is not available for testing, a positive
diagnosis in a patient can help guide PEP in other bite victims if
they have remained asymptomatic; these victims should receive
PEP even months after the bite.54 The laboratory diagnosis of rabies
in humans is also a priority particularly when PEP with adequate
and adequately conserved vaccine has been undertaken and failed,
in order to identify the virus.16,55 Finally, the laboratory diagnosis
of rabies in endemic settings provides reliable, laboratory-
conﬁrmed data to complete the few existing estimations of rabies
burden documented in humans as part of research efforts.4,56
Findings from such research projects are crucial to increase
awareness about the rabies burden among policy-makers and to
prioritize resources towards its control.
4. Using diagnostic techniques in the operational setting
4.1. Performance issues
Assays used will vary, depending on the time elapsed since
infection or the objective sought (Figure 1). In practice, direct
diagnosis by RABV protein detection using DFAT is the reference
technique that should be implemented in national reference
laboratories whenever possible. Direct diagnosis by detection of
genome fragments using PCR-based assays must be used only by
experienced teams, bearing in mind that this technique is based on
validated in-house tests and not standardized, commercially
available kits. Cell culture isolation of the virus is usually reserved
for reference laboratories and research. Isolation of the virus, as
well as PCR-based methods, may be used as a second-line test to
conﬁrm negative results of other tests such as DFAT in animals, or
in the case of isolation to amplify live virus from original samples.
In post-mortem human brain samples, DFAT and PCR-based
techniques are highly effective for the detection of RABV antigen
and genome, respectively. In such samples, RT-PCR and RT-qPCR
are useful alternatives to DFAT (Figure 1). These assays can also be
used to test saliva or nuchal skin biopsy samples for intra vitam or
post-mortem diagnosis in humans.
4.2. Operational issues
The choice of assay may vary depending on the nature of the
sample to be tested and also its state of preservation29,57 (Figure 1).
DFAT, for example, remains less expensive than RT-PCR and can be
used to test samples locally, however the latter remains more
effective when testing degraded samples.21 In many endemic
settings, the absence of a comprehensive network to transport
samples to the laboratory makes it difﬁcult to maintain staff
competence in DFAT, and ﬂuorescent conjugates may reach their
expiry date before being fully used. Method simplicity, the
availability of laboratory equipment, and the cost and ease of
maintenance of this equipment are important factors to consider in
the choice of laboratory assays before their implementation.29
Rabies is classiﬁed as a hazard group 3 pathogen,58,59 but a level
2 biosafety laboratory (BSL-2) is considered adequate containment
for diagnosis and other activities, as long as they are performed by
duly immunized personnel and are not associated with a high
potential for droplet or aerosol production and do not involve large
quantities or high concentrations of infectious material.16,60
Diagnosis and routine activities are undertaken by trained and
duly immunized personnel in BSL-2 laboratories in most rabies-
endemic developing settings that do not routinely have BSL-3
laboratory capacity.
Figure 1. Proposed rabies testing algorithm based on the objectives of testing and the methods to be used in a specialized laboratory.
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Testing live animals for ongoing suspected rabies is not
recommended16 (Figure 1). Animals should be quarantined for
10–14 days (depending on local regulations) or, in the case of
suspected rabies, be humanely euthanized with no damage to
the head. Brain samples can then be analyzed in the laboratory
setting.8,61 One set of tools should be used for each specimen.
The brain must be extracted from the animal’s cranium by
trained and immunized personnel in a safe and dedicated
laboratory with a clean autopsy table and sterilized equipment.
These precautions will prevent false-positive results due to
sample contamination. After extracting the brain attached to the
cerebellum and medulla oblongata, tissue samples should be
taken from more than one site among Ammon’s horns
(hippocampus) and the medulla oblongata (in the brainstem).
Additional recommended samples include the following: cere-
bral tissue for OIE,62 cerebral and/or cerebellar tissue for
WHO,8,16 and cerebellar tissue for the US CDC.63 The testing
of all four sites is recommended in the Russian Federation and
other countries of the former Soviet Union.64 Aside from organ
transplantation, rabies is almost never transmitted by blood or
body ﬂuids.65,66 Standard precautions nevertheless apply to
protect the safety of personnel, even after veriﬁcation that they
have been properly immunized.2,67 A pipette or a straw can also
be used to rapidly collect brain samples during ﬁeld studies in
wild or domestic animals, or when necropsy of all animal heads
is impossible due to too many samples coming to the laboratory
for testing.17,614.4. Practical issues of rabies diagnosis in humans
As in animals, post-mortem diagnosis in humans can easily be
performed on brain samples obtained in a pathology laboratory, as
above. Autopsies, however, are increasingly refused by next of kin
for cultural reasons, or when funeral rites must be performed
without delay.68 If a post-mortem autopsy cannot be performed for
a human subject, minimally invasive methods may be used to
sample tissue for rabies diagnosis while respecting the corpse’s
integrity (Figure 2).
Early studies of intra vitam diagnosis found RABV antigens in
hair follicle nerves of human rabies cases.69 This paved the way for
testing of skin biopsies sampled with hair follicles at the nape of
the neck, obtained by excision or punch biopsy.19 Nuchal skin
biopsies can be performed post-mortem but also intra vitam in
sedated patients. An optimal diagnostic strategy will associate
nuchal biopsy with testing of at least three consecutive saliva
samples (ideally at 3–6 h intervals), which is highly speciﬁc and
sensitive, irrespective of the time of collection (i.e., 1 day after the
onset of symptoms until just after death).19,70 Two other minimally
invasive methods for post-mortem brain sampling without
craniotomy in humans have also been described: sub-occipital
cisternal puncture and the retro-orbital route using a catheter
(Figure 2).32,71 A trans-nasal route has also been described.72
4.5. Shipment issues
Nuchal samples are best shipped frozen, but can be shipped
simply with ice packs. Saliva samples should be shipped frozen.
Figure 2. Minimally invasive tissue sampling techniques for rabies diagnosis in humans.
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solution if freezing is not readily available.10,17,73 Samples should
never be preserved in formalin. The reference laboratory must be
contacted before the shipment of samples with suspected RABV.
They should be sent in a double-enclosed waterproof container,
with cooling material and absorbent material. All of these should
be placed in a leak-proof outer container, in observance with
national and International Air Transport Association (IATA)
guidelines as ‘category B’ necessitating UN 3373/650 packaging
(only RABV cultures are considered ‘category A’).75,75 Sampling and
shipping procedures must be well-established and communicated
effectively to laboratory staff before they have to be put into use.
Samples may be sent on ﬁlter paper at ambient temperature for
easier shipment.76,77 Filter paper such as FTA also has the
advantage of inactivating RABV, reducing the hazard and
facilitating shipment while preserving nucleic acids.
5. Conclusions
The laboratory diagnosis of rabies is imperative to guide public
health measures in non-endemic settings, document protection
(intra vitam serology on vaccinees’ blood samples), and to conduct
research (seroprevalence studies, death despite timely PEP).
Although laboratory testing is desirable, it is extremely limited
in resource-poor settings and/or rural areas of endemic countries,
where most cases occur worldwide. Public health surveillance
needs in the endemic setting with high caseloads may therefore be
satisﬁed by resorting to syndromic case deﬁnitions and past
history of a dog bite.49,78,79 Diagnosis based on molecular biology
tests and virus isolation, however, may help guide PEP, is especially
useful in ‘paralytic’ rabies cases, and may provide information on
phylogeny for documenting the introduction/emergence of RABV
in a geographic area.31 As the epidemiological situation evolves,
the strategy should shift from that suited for an endemic setting to
one adapted to a non-endemic setting. Many assays available to
date are sensitive and speciﬁc but must be implemented by an
experienced team with uninterrupted supplies. Rapid tests (dRIT
and RIDT) have recently been developed, offering the possibility for
ﬁrst-line rabies laboratory diagnosis in less-equipped laboratoriesor in more remote areas. Should further external validation of the
RIDT conﬁrm its initial performance and usability in both saliva
and brain samples,13–15 this assay may become a good alternative
in the ﬁeld, for example in provincial hospitals or vaccination
centres where reference laboratory methods of diagnosis are not
readily available. The same is true for dRIT when reagents become
standardized and available on a regular basis, with adequate
quality control.
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